NEW YORK, June 23, 2017 /PRNewswire/ --
If you want a Stock Review on ONVO, BCR, BRKR or DXCM then come over to http://dailystocktracker.com/register/and sign up for your free customized report today. Today's research on DailyStockTracker.com is centered on Healthcare, which has been a closely watched sector of the market, as the White House and the Republican-majority Congress attempt to repeal and
San Diego, California headquartered Organovo Holdings Inc.'s stock finished Thursday's session 1.50% higher at $2.71 with a total trading volume of 582,840 shares. The stock is trading below their 50-day moving average by 2.83%. Shares of the Company, which focuses on developing and commercializing functional human tissues that could be employed in drug discovery and development, biological research, and as therapeutic implants for the treatment of damaged or degenerating tissues and organs, have a Relative Strength Index (RSI) of 46.20.
On June 07th, 2017, Organovo Holdings reported financial results for Q4 FY17. Total revenue for the quarter was $0.8 million; net loss was $10.7 million; product and service revenue was $0.8 million; cost of revenues was $0.2 million; research and development costs were $5.5 million; and selling, general and administrative expenses were $5.8 million. The Company also ended Q4 Fy17 with cash and cash equivalents balance of $62.8 million. Your complete research report on ONVO can be retrieved for free at:
Shares in Murray Hill, New Jersey headquartered C.R. Bard Inc. rose 0.31%, ending yesterday's session at $315.98 with a total trading volume of 614,296 shares. The stock has gained 2.48% in the past month, 27.04% in the previous three months, and 40.65% on an YTD basis. The Company's shares are trading 5.30% above their 50-day moving average and 27.98% above their 200-day moving average. Moreover, shares of C.R. Bard, which together with its subsidiaries, designs, manufactures, packages, distributes, and sells medical, surgical, diagnostic, and patient care devices worldwide, have an RSI of 68.48.
On June 14th, 2017, C.R. Bard's Board of Directors declared a regular quarterly dividend of 26 cents per share on the Company's common stock. The current indicated annual dividend rate is $1.04 per share. The dividend is payable on August 04th, 2017, to shareholders of record at the close of business on July 24th, 2017. A free report on BCR is just a click away at:
On Thursday, Billerica, Massachusetts headquartered Bruker Corp.'s stock climbed 0.42%, to close the day at $28.62. A total volume of 451,406 shares was traded. The Company's shares have advanced 6.32% in the last one month, 23.26% in the previous three months, and 35.13% on an YTD basis. The stock is trading 11.49% and 22.38% above its 50-day and 200-day moving averages, respectively. Additionally, shares of Bruker, which develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions worldwide, have an RSI of 72.67.
On June 01st, 2017, Bruker introduced major innovations for strain typing, hospital hygiene, and infection control at the American Society for Microbiology Microbe 2017 meeting. The novel, bench-top IR Biotyper system for microbial strain typing is based on Fourier-Transform Infrared spectroscopy technology, and complements the Company's world-leading MALDI Biotyper mass spectrometry platform for fast microbial identification from cultures using protein fingerprinting. Sign up for your complimentary research report on BRKR at:
Shares in San Diego, California headquartered DexCom Inc. ended the day 0.45% higher at $78.68. A total volume of 770,738 shares was traded. The stock has gained 16.42% in the last one month, 3.42% in the previous three months, and 31.79% since the start of this year. The Company's shares are trading above their 50-day and 200-day moving averages by 8.06% and 3.61%, respectively. Furthermore, shares of DexCom, which together with its subsidiaries, focuses on the design, development, and commercialization of continuous glucose monitoring systems in the US and internationally, have an RSI of 67.99.
On June 20th, 2017, DexCom announced that it plans to release its Q2 2017 financial results after market close on Tuesday, August 01st, 2017. Management will hold a conference call to review the Company's Q2 2017 performance starting at 4:30 p.m. ET on the same day. The conference call will be concurrently webcast on the Company's website. Register for free on DailyStockTracker.com and download the latest research report on DXCM at:
Daily Stock Tracker:
Daily Stock Tracker (DST) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. DST has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
DST has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email [email protected]. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by DST. DST is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
DST, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. DST, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, DST, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither DST nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: [email protected] Phone number: (207)331-3313 Office Address: 377 Rivonia Boulevard, Rivonia, South Africa
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA
Subscribe to our Free Newsletters!
Hyperacusis is a chronic hearing disorder characterized by an abnormal sensitivity to s ...
Proton beam therapy is a type of external radiation treatment or radiotherapy that uses protons ...
Statins are a group of drugs which help to lower the blood cholesterol levels.View All